SEC-sourced researchBeta

KRYS

Krystal Biotech, Inc.

US markets

Data passport

CIK: 0001711279
Exchange: Nasdaq
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Sep 16, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 9:09 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

KRYS · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	50,699,000.0000	Feb 17, 2026
December 2024	290,515,000.0000	Feb 17, 2026
December 2025	389,130,000.0000	Feb 17, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	389,130,000.0000	204,831,000.0000	200,865,000.0000	1,333,794,000.0000	114,234,000.0000	Feb 17, 2026
December 2024	290,515,000.0000	89,159,000.0000	123,420,000.0000	1,055,838,000.0000	109,458,000.0000	Feb 17, 2026
December 2023	50,699,000.0000	10,932,000.0000	-88,804,000.0000	—	—	Feb 17, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$389.13M	December 2025	Feb 17, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$290.52M	December 2024	Feb 17, 2026	10-K
Net incomeNetIncomeLoss	$204.83M	December 2025	Feb 17, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$200.87M	December 2025	Feb 17, 2026	10-K
Total assetsAssets	$1.33B	December 2025	Feb 17, 2026	10-K
Total liabilitiesLiabilities	$114.23M	December 2025	Feb 17, 2026	10-K

New filings

Explore methodology ↗